![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-desktop-headergif-63893.gif)
![SPI Pharma Corp Ad](https://www.pharmacompass.com/image/flap/spi-pharma-corp-ad-w36-mobile-headergif-78265.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.indianpharmapost.com/news/astellas-completes-acquisition-of-propella-therapeutics-15067
https://www.prnewswire.com/news-releases/astellas-to-acquire-propella-therapeutics-301989842.html
https://www.globenewswire.com/news-release/2023/02/14/2607588/0/en/Propella-Therapeutics-Announces-Presentation-of-Updated-Phase-1-2a-Data-of-PRL-02-for-the-Treatment-of-Advanced-Prostate-Cancer-at-2023-ASCO-Genitourinary-GU-Cancers-Symposium.html
https://www.globenewswire.com/news-release/2022/09/08/2512425/0/en/Propella-Therapeutics-Announces-Presentation-of-Phase-1-2-Data-of-PRL-02-for-the-Treatment-of-Advanced-Prostate-Cancer-at-ESMO-Congress-2022.html
https://www.globenewswire.com/news-release/2022/04/07/2418425/0/en/Propella-Therapeutics-Announces-Licensing-Agreement-with-Jiangsu-Aosaikang-Pharmaceutical-Co-Ltd-ASK-Pharm-for-Development-and-Commercial-Rights-to-CGS-200-5-in-Greater-China.html
https://www.globenewswire.com/news-release/2021/06/29/2254676/0/en/Propella-Announces-First-Patient-Dosed-in-Phase-1-2a-Trial-of-PRL-02-for-Treatment-of-Metastatic-Prostate-Cancer.html
https://www.prnewswire.com/news-releases/propella-therapeutics-receives-fda-clearance-to-begin-phase-1-clinical-study-of-novel-prostate-cancer-treatment-301295133.html
https://www.prnewswire.com/news-releases/propella-therapeutics-partners-with-national-cancer-institute-to-develop-new-treatment-for-metastatic-prostate-cancer-301233411.html